QCI, QIAGEN’s Clinical Decision Support Platform, Surpasses Three Million NGS Patient Test Cases
REDWOOD CITY, CA & HILDEN, GERMANY–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAGEN Clinical Insights (QCI) decision support software platform has been used to date to interpret more than three million profiles molecular patient data for hereditary and oncological diseases. This milestone for QCI’s portfolio of clinical software and professional services for interpretation and variant reporting of next-generation sequencing (NGS) assays underscores QIAGEN’s leadership position in precision medicine. The platform, launched only seven years ago, is currently growing by 35%, or 700,000 additional cases per year, outperforming other commercial offerings by a factor of 5 in terms of patient cases.
The QCI portfolio is an integrated and universal solution for secondary and tertiary analysis in molecular pathology, clinical genetics and translational research that can be used with any sequencing platform. Comprised of QCI Secondary Analysis, QCI Interpret, and QCI Precision Insights, the portfolio streamlines NGS data analysis and variant interpretation, allowing users to move from raw NGS data to clinical reporting quickly and with confidence.
“Surpassing three million patient cases reported using our QCI solution demonstrates how ubiquitous our bioinformatics solutions are becoming in the standard of patient care. This is in line with our ambition to deliver on the promise of precision medicine,” said Jonathan Sheldon, Executive Vice President of QIAGEN Digital Insights. “The cost and speed of NGS testing is no longer a barrier to adoption. It’s the downstream analysis, interpretation and quality reporting of complex results that becomes the bottleneck, and it’s is where our QCI portfolio fits in. Laboratories can confidently adopt and scale NGS with our NGS interpretation and reporting tools using our advanced Augmented Molecular Intelligence (AMI), regardless of the platform of sequencing they use. Today, more than 200 scientific experts work alongside machines to efficiently organize, annotate, and analyze complex clinical evidence essential to accurate, high-quality reports. This emphasis on human effort, review and certification is key. This means our customers can trust the data and proceed confidently with the most up-to-date information.”
The core content of the QCI Portfolio, the QIAGEN Knowledge Base, is powered by AMI. It combines artificial intelligence (AI) and human expertise to confidently advance and accelerate clinical decision-making. A key differentiator in the QCI portfolio, AMI’s application leverages AI and machine learning to efficiently identify, extract and align evidence from scientific literature and over 40 public and proprietary databases in the QIAGEN Knowledge Base. The approach ensures high-quality molecular intelligence that users can trust to improve their own decisions.
“One of the biggest challenges in whole genomic profiling (CGP) is bioinformatics. QIAGEN’s QCI Interpret software allowed our lab to confidently transition from a targeted 177 gene panel to a 718 gene CGP panel, while helping us reduce cost, time and labor said Petr Starostik, MD, director of molecular pathology, University of Florida Health Pathology Laboratories. “The quality of the QIAGEN Knowledge Base content is unmatched in the industry. From a large, complex panel, we can filter and classify variants according to AMP and NCCN guidelines and create personalized, patient-specific reports with the latest diagnostic, prognostic and therapeutic information. With so much data to process now, QCI Interpret provides the information we need to make the right decisions.
As the NGS industry is poised to transform significantly with the introduction of faster and less expensive NGS instruments, it expects to see accelerated adoption of analysis, testing and screening genetics. As more vendors enter the market, customer demand for dedicated applications and solutions that consider front-end sample processing and downstream bioinformatics will further accelerate. QIAGEN has built an extensive NGS application and portfolio strength aligned with key market drivers to meet these demands and will continue to invest in its expansion to support industry growth and complement Sample to Insight solutions for its customers. and partners.
Learn more about the QCI portfolio here.
About QIAGEN Digital Insights
QIAGEN Digital Insights, the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical insights, analysis and interpretation tools and services for scientists and clinicians. We have over 25 years of industry experience, 90,000 users worldwide, over 100,000 citations in scientific articles, over 3 million patient cases profiled and over 40 billion scientific data points . Discover our portfolio of expert-curated genomic and clinical knowledge solutions, as well as bioinformatics software and services for efficient management and sharing of data and actionable insights. Learn more about https://digitalinsights.qiagen.com/.
QIAGEN NV, a Netherlands-based holding company, is the world’s leading provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant and actionable insights. Automation solutions connect them in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in molecular diagnostics (human health), applied testing (primarily forensics), pharmacy (pharmaceutical and biotechnology companies), and academia (research in life sciences). As of March 31, 2022, QIAGEN employed over 6,000 people at over 35 locations worldwide. Further information can be found at https://www.qiagen.com/.
Certain statements in this press release may be deemed forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein regarding QIAGEN’s products, collaboration markets, strategy or results of operations, including, without limitation, its adjusted net sales and results adjusted diluted expected, are forward-looking statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These uncertainties and risks include, but are not limited to, risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability operating results and allocations between customer categories; business development of markets for our products to customers in academia, pharmaceuticals, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected technological changes; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customer funding, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competing products; market acceptance of new QIAGEN products and integration of acquired technologies and businesses. For more information, please refer to discussions in reports that QIAGEN has filed with or provided to the United States Securities and Exchange Commission (SEC).
Source: QIAGEN AG